BCAX — Bicara Therapeutics Inc. Stock Price, Chart & AI Report

Positive Feb 26, 2026 • 21:01 UTC Benzinga • Globe Newswire

Bicara Therapeutics Announces Closing of Oversubscribed Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Bicara Therapeutics (NASDAQ: BCAX) successfully closed an oversubscribed public offering, raising approximately $172.5 million in gross proceeds through the sale of 8,581,250 common shares and 2,200,000 pre-funded warrants. The underwriters fully exercised their option to purchase additional shares. The company plans to use the proceeds to advance its lead program ficerafusp alfa, a first-in-class bifunctional antibody for solid tumors, including regulatory filing and commercial launch preparations, manufacturing costs, and clinical development acceleration.

BCAX public offering capital raise biopharmaceutical ficerafusp alfa clinical-stage solid tumors EGFR

Sentiment note

The company successfully closed an oversubscribed public offering with full exercise of underwriters' option, demonstrating strong investor demand. The $172.5 million capital raise provides substantial funding to advance its lead therapeutic candidate through regulatory and commercial milestones, supporting development acceleration and manufacturing expansion.

Positive Feb 25, 2026 • 04:13 UTC GlobeNewswire Inc. • Na

Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded Warrants

Bicara Therapeutics priced a $150 million underwritten public offering of 7.175 million common shares at $16.00 per share and 2.2 million pre-funded warrants. The company plans to use proceeds to advance its lead candidate ficerafusp alfa, build commercial infrastructure, accelerate development in head and neck cancer, and fund manufacturing and expansion efforts. The offering is expected to close on February 26, 2026.

BCAX public offering capital raise ficerafusp alfa bifunctional antibody head and neck squamous cell carcinoma EGFR TGF-β

Sentiment note

The company successfully priced a substantial $150 million capital raise with strong investor demand, indicating market confidence. The proceeds will fund advancement of their lead therapeutic candidate through regulatory filing and commercial launch, accelerate clinical development, and expand manufacturing capabilities—all positive indicators for near-term progress and value creation.

Positive Feb 24, 2026 • 21:01 UTC Benzinga • Globe Newswire

Bicara Therapeutics Announces Proposed Public Offering of Common Stock

Bicara Therapeutics (NASDAQ: BCAX), a clinical-stage biopharmaceutical company, announced a proposed underwritten public offering of $150 million in common stock with a 30-day option for underwriters to purchase an additional $22.5 million. The company plans to use proceeds to advance its lead drug ficerafusp alfa, build commercial infrastructure, and support regulatory filings and commercial launch efforts.

BCAX public offering biopharmaceutical ficerafusp alfa capital raise clinical-stage solid tumors EGFR

Sentiment note

The company is raising $150 million in capital to advance its lead therapeutic candidate ficerafusp alfa through regulatory approval and commercial launch, demonstrating investor confidence and providing resources to accelerate development. The funding supports expansion of medical and commercial infrastructure, which indicates progress toward commercialization of a first-in-class bifunctional therapy.

Positive Dec 15, 2025 • 13:00 UTC GlobeNewswire Inc. • Claire Mazumdar

Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12

Bicara Therapeutics will present at the J.P. Morgan 2026 Healthcare Conference, highlighting its lead program ficerafusp alfa, a bifunctional antibody designed to treat solid tumor cancers by targeting EGFR and TGF-β.

BCAX biopharmaceutical oncology clinical-stage bifunctional antibody solid tumors

Sentiment note

Company is advancing its lead therapeutic candidate ficerafusp alfa, demonstrating consistent response rates and progressing towards pivotal study dose selection in head and neck cancer treatment

Positive Dec 6, 2025 • 13:00 UTC GlobeNewswire Inc. • Bicara Therapeutics

Bicara Therapeutics’ Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026

Bicara Therapeutics reported promising Phase 1b data for ficerafusp alfa, a bifunctional antibody, in treating HPV-negative head and neck squamous cell carcinoma. The 750mg weekly dose showed a 57% confirmed overall response rate and was well-tolerated when combined with pembrolizumab.

BCAX ficerafusp alfa head and neck cancer immunotherapy clinical trials TGF-β inhibition

Sentiment note

Demonstrated promising clinical trial results with a 57% overall response rate, consistent safety profile, and potential for meaningful patient outcomes in head and neck cancer treatment

Positive Oct 27, 2025 • 12:30 UTC Benzinga • Prnewswire

Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology

Oncology drug delivery is advancing through nanomedicine technologies, with companies developing innovative platforms to improve drug bioavailability, reduce toxicity, and enhance therapeutic effectiveness in cancer treatments.

IOBT NVS BCAX PFE nanomedicine drug delivery oncology bioavailability

Sentiment note

Received FDA Breakthrough Therapy Designation for ficerafusp alfa in head and neck cancer treatment

Positive Jun 1, 2025 • 17:12 UTC GlobeNewswire Inc. • N/A

Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025

Bicara Therapeutics presented updated data from its Phase 1/1b clinical trial of ficerafusp alfa in combination with pembrolizumab in patients with first-line recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). The data showed deep and durable responses, with a median duration of response of 21.7 months and a median overall survival of 21.3 months.

BCAX Bicara Therapeutics ficerafusp alfa pembrolizumab head and neck squamous cell carcinoma HNSCC

Sentiment note

The article presents positive data from Bicara Therapeutics' clinical trial, showing deep and durable responses with its lead product candidate ficerafusp alfa in combination with pembrolizumab in HNSCC patients. This suggests the potential for Bicara's therapy to address a significant unmet need in this patient population.

Positive May 22, 2025 • 21:00 UTC GlobeNewswire Inc. • N/A

Bicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 ASCO Annual Meeting

Bicara Therapeutics announced the publication of updated interim data from its Phase 1/1b trial of ficerafusp alfa in combination with pembrolizumab for first-line recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). The data will be presented at the 2025 ASCO Annual Meeting.

BCAX Bicara Therapeutics ficerafusp alfa pembrolizumab head and neck squamous cell carcinoma ASCO Annual Meeting

Sentiment note

The article highlights positive interim data from Bicara's Phase 1/1b trial of ficerafusp alfa, which demonstrated encouraging signals and a meaningful improvement over historical benchmarks in patients with HPV-negative HNSCC, a population with high unmet need. The company is presenting the fulsome dataset at the ASCO Annual Meeting, indicating progress in the development of their lead program.

Positive Apr 23, 2025 • 14:00 UTC GlobeNewswire Inc. • N/A

Bicara Therapeutics to Present Updated Data from Ongoing Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Bicara Therapeutics announced that updated data from its ongoing Phase 1/1b clinical trial of ficerafusp alfa in first-line recurrent/metastatic head and neck squamous cell carcinoma will be presented at the 2025 ASCO Annual Meeting.

BCAX Bicara Therapeutics ficerafusp alfa Phase 1/1b trial head and neck squamous cell carcinoma ASCO Annual Meeting

Sentiment note

The article highlights Bicara Therapeutics' upcoming presentation of updated data from its ongoing clinical trial, which suggests progress in the development of its lead product candidate, ficerafusp alfa, for the treatment of head and neck cancer.

Positive Sep 16, 2024 • 20:01 UTC Benzinga • Globe Newswire

Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Bicara Therapeutics, a clinical-stage biopharmaceutical company, announced the closing of its $362 million initial public offering on the Nasdaq Global Market under the ticker symbol 'BCAX'.

BCAX Bicara Therapeutics IPO Nasdaq biopharmaceutical

Sentiment note

The company successfully completed a $362 million IPO, indicating investor confidence in its potential as a clinical-stage biopharmaceutical company.

Positive Sep 16, 2024 • 20:01 UTC GlobeNewswire Inc. • N/A

Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Bicara Therapeutics, a clinical-stage biopharmaceutical company, has announced the closing of its $362 million initial public offering on the Nasdaq Global Market under the ticker symbol 'BCAX'.

BCAX Bicara Therapeutics Initial Public Offering Nasdaq Biopharmaceutical

Sentiment note

The article announces the successful closing of Bicara Therapeutics' $362 million initial public offering, which is a positive development for the company as it raises significant capital to fund its clinical-stage biopharmaceutical operations.